Recent News

Cambrooke Therapeutics events and news.

New PKU Evidence Published Today!

Read the details of this key study using Cambrooke’s Glytactin™, made with GMP, a natural whole protein, for the nutritional management of PKU. Study published in the American Journal of Clinical Nutrition: “Glycomacropeptide for the nutritional management of phenylketonuria: a randomized, controlled, crossover trial.”…read article

KetoVie Café Pizza Petites 3:1 Added to the Cambrooke Therapeutics Line of Ketogenic Diet-Friendly Foods

AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the introduction of a kid-favorite food with its KetoVie Café Pizza Petites 3:1. Cambrooke Therapeutics Inc., has introduced a kid-favorite food with its KetoVie Café Pizza Petites 3:1 With the launch of KetoVie Café Pizza Petites…

Details

Cambrooke expands its KetoVie Café food line with the launch of KetoVie Café Donut Delights – Cinnamon 3:1.

AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, expands its KetoVie Café food line with the launch of KetoVie Café Donut Delights – Cinnamon 3:1. Cambrooke Therapeutics expands its KetoVie Café food line with the launch of Donut Delights – Cinnamon 3:1. Cambrooke Therapeutics continues to…

Details

Cambrooke announces the closing of the Series C investment round, led by Seventure Partners (Paris, France), an asset manager, investing out of its latest healthcare and nutrition focused Health For Life Capital™ vehicle

AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics, Inc. (“Cambrooke”), a global therapeutic nutrition innovator, is pleased to announce the closing of the Series C investment round, led by Seventure Partners (Paris, France), an asset manager, investing out of its latest healthcare and nutrition focused Health For Life CapitalTM vehicle. Seventure is joined by Cambrooke’s existing main investor, Galen Partners…

Details

Cambrooke announces the KetoVie Peptide, a groundbreaking hydrolyzed protein-based ketogenic formula for children with intractable epilepsy

AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics, Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the launch of the first and only ketogenic hydrolyzed whey-based (peptides) formula, designed for individuals on a ketogenic diet who have milk protein sensitivities and/or impaired digestive function. Because of its peptide protein formulation, KetoVie™…

Details

Cambrooke Therapeutics Announces Launch of New Family of Medical Foods for Inborn Errors of Metabolism

AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the introduction of an advanced family of amino acid-based medical foods for the dietary management of several disorders of amino acid metabolism. These disorders include Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Isovalaric Acidemia (IVA),…

Details